8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 15, 2026·SEC
Material company update
Mar 16, 2026·SEC
Structure Therapeutics Inc.(GPCR)Earnings, Financials & Key Ratios
GPCR•NASDAQ
$54.75
Price updated Jul 6, 2026
AboutStructure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.Show more
- Revenue$0
- EBITDA-$284M-80.4%
- Net Income-$141M-15.2%
- EPS (Diluted)-2.40-2.6%
- ROE-11.86%+36.2%
GPCR Price & Volume
Structure Therapeutics Inc. (GPCR) stock price & volume — 10-year historical chart
Loading chart...
Clinical Scaling Drives Aggressive R&D Expenditure
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:Clinical trial execution failure
Key Thesis Takeaways
- Structure Therapeutics remains a high-risk, pre-revenue biotechnology firm whose valuation is entirely contingent upon the successful clinical advancement of its GPCR-targeted metabolic pipeline.
- While the company maintains a substantial liquidity buffer of $316.2 million as of 2026Q1, the rapid escalation of quarterly R&D costs to $66.7 million suggests a precarious path toward commercialization.
- Investors should monitor the firm's ability to achieve pivotal milestones without further dilutive financing, as current operating losses have widened to $89.6 million.
Verdict Logic
while the $316.2 million cash position provides near-term stability, the lack of revenue and the widening $89.6 million quarterly operating loss warrant a cautious, wait-and-see approach regarding clinical data readouts.
GPCR Growth Metrics
Structure Therapeutics Inc. (GPCR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-19.01%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-2.33%
Return on Capital
10 Years-40.21%
5 Years-39.32%
3 Years-28.63%
Last Year-24.09%
GPCR Recent Earnings
Structure Therapeutics Inc. (GPCR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.35+10.3%
$0.39
Rev
—
$11M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.49-40.0%
$0.35
Rev
—
$9M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.37-2.8%
$0.36
Rev
—
—
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.36-28.6%
$0.28
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.35vs $0.39+10.3% | —vs $11M |
| Q1 2026 | Feb 26, 2026 | $0.49vs $0.35-40.0% | —vs $9M |
| Q4 2025 | Nov 6, 2025 | $0.37vs $0.36-2.8% | — |
| Q3 2025 | Aug 6, 2025 | $0.36vs $0.28-28.6% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Structure Therapeutics Inc. (GPCR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $54.75 | $3.15B | -22.81 | — | — | -11.86% | — | |
| $1.56 | $190.96M | -1.08 | -84.2% | -323.49% | -174.71% | — | |
| $189.99 | $40.39B | -31.93 | — | — | -83.22% | — | |
| $114.76 | $9.37B | -31.10 | -16.72% | -612.17% | -25.02% | — | |
| $86.55 | $12.19B | -7094.26 | 23258.15% | -48.38% | -55.09% | — | |
| $17.81 | $1.09B | -4.79 | — | — | -51.45% | — |
Compare GPCR vs Peers
Structure Therapeutics Inc. (GPCR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GPCR SEC Filings & Documents
Structure Therapeutics Inc. (GPCR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when GPCR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GPCR Frequently Asked Questions
Structure Therapeutics Inc. (GPCR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is GPCR profitable?
Structure Therapeutics Inc. (GPCR) reported a net loss of $170.6M for fiscal year 2025.
Dividend & Returns
What is GPCR's return on equity?
Structure Therapeutics Inc. (GPCR) has a return on equity (ROE) of -11.9%. Negative ROE indicates the company is unprofitable.
What is Structure Therapeutics Inc.'s free cash flow?
Structure Therapeutics Inc. (GPCR) had negative free cash flow of $159.2M in fiscal year 2025, likely due to heavy capital investments.